Joint; DerangementMOVIPLUSNCT06714851
Chondractiv Move on Activity-related Joint Discomfort
A study testing Chondractiv Move in people with Joint; Derangement, run by Symrise Group at 1 site in France.
Trial summary
Joint discomfort, manifested as knee pain or gonalgia, is a common problem not only among athletes, but also among people who regularly take part in physical activities and sports. This discomfort can limit mobility and flexibility, even in healthy people who do not suffer from osteoarthritis or other joint diseases. Read more about this study
- Who is it for?
- Ages 30 to 65 years
- Conditions the study is for
- Joint; Derangement
- What is being tested?
- Chondractiv Move
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 144 participants
- Where
- 1 siteFrance
- Study dates
- 25 Nov 2024to 9 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Body mass index ≥ 18.5 and < 30.0 kg/m2.
- Physically active: joint bearing sports (i.e., but not limited to soccer, basketball, handball, volleyball, tennis, running) for at least 3 hours per week or 2 times per week.
- Who self-report activity-related discomfort or reversible knee-joint discomfort during or immediately after physical activity over a period of at least 2 months.
- Who experience pain intensity of 5 (out of 10 on the 11 point-NRS) during the stress joint test (SLSD) and perform at least 25 repetitions.
- Who have no trouble swallowing capsules
- Having a smartphone allowing using the e-PRO App NursTrial®.
- Affiliated to a French Health insurance scheme.
- Signed informed consent.
Who cannot join
- With diagnosed injury/trauma or tendinopathy (wiper syndrome, patellofemoral syndrome, meniscopathy), algodystrophy, osteoarthritis, rheumatic arthritis or inflammation, or other knee or joint disease.
- Extreme pain symptoms that required high-dose analgesic therapy over a longer period (>2 weeks) or intra-articular injection treatment.
- Untreated or unstable hypothyroidism, or evidence of any neurological disorders.
- Known hypersensitivity to one of the components of the experimental products (i.e., dog rose).
- Intra-articular injections or infiltrations with hyaluronic acid, plasma-rich platelet, glucosamine, chondroitin, or supplementation, with glucosamine, chondroitin, collagen-based products in the last 3 months, or spa therapy related to join health in the last 6 months.
- Current intake of corrective treatment, plant-based products or dietary supplements that could interfere with joint, tendon or bone metabolism.
Show all 10Show fewer
- May not be compliant or may not respect the constraints imposed by the protocol (i.e., stable physical activities and dietary habits throughout the study).
- Enrolled in another clinical trial or being in a period of exclusion from a previous clinical trial.
- For woman of childbearing age (neither menopausal, nor hysterectomised, nor sterilized): not using effective contraception (oral contraceptives, intra-uterine device, contraceptive implant, or condoms).
- Belonging to a population covered by articles L.1121-5 (pregnant confirmed by urinary test at inclusion or breastfeeding women), L.1121-6 (persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care), and L.1121.8 (adults under legal protection or unable to express their consent) of the CSP (French Public Health Code).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Chondractiv Move (Dietary Supplement) on Activity-related Joint Discomfort in Physically Active Subjects: a Double-blind, Randomized, Placebo-controlled Study
Joint discomfort, manifested as knee pain or gonalgia, is a common problem not only among athletes, but also among people who regularly take part in physical activities and sports. This discomfort can limit mobility and flexibility, even in healthy people who do not suffer from osteoarthritis or other joint diseases. Functional joint discomfort is also due to joint stress and the short-term deterioration of cartilage. The processes of cartilage formation and degradation lose their balance under load, and discomfort is felt for some time after exercise. These conditions and symptoms occur long before the onset of a disease such as osteoarthritis.
Dietary supplements based on herbs or collagen derivatives (a protein involved in maintaining the structure of tissues, including those of the joints) are frequently used to alleviate the discomfort associated with joint disorders and improve the balance between cartilage synthesis and degradation.
This study aims to assess the effect of the dietary supplement "Chondractiv Move" (named "Chondractiv Boost" at the time of protocol writing) on joint discomfort induced by physical activity. This is a combination of rosehip extract and hydrolyzed chicken cartilage containing collagen type II, chondroitin sulfate, and hyaluronic acid as main actives. This combination is chosen based on the results of studies showing the beneficial effects on joints of the ingredients.
Read the detailed description
This study requires the inclusion of about 140 participants who regularly take part in sporting activities and report knee pain during and/or after this activity.
Participants are randomly assigned to the control group receiving a placebo (a neutral product based on maltodextrins with no effect), or to the test group receiving the dietary supplement. This study is a double-blind, randomized controlled trial. This means that participants as well as assessors do not know the allocation group. This is a necessary procedure to guarantee impartiality in clinical trials.
Participants ingest placebo or dietary supplement for 8 consecutive weeks (or 12 weeks in the ancillary group with extended supplementation duration).
To assess the effect of supplementation, participants are asked to attend medical check-ups and complete questionnaires, before starting the treatment to determine basal values, and then at regular intervals, i.e. every 2 weeks or every month.
Throughout their participation, participants are monitored by the study doctor and must go to a clinical investigation center for doctors visits.
- Conditions
- Joint; Derangement
- Being tested
- Chondractiv Move, Placebo
- Keywords
- Activity-related joint discomfort, Collagen hydrolysate
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chondractiv MoveDietary supplement
The dietary supplement under study (Chondractiv Move) is a combination of 2 active ingredients: Hydrolyzed chicken cartilage and Rosehip extract at the dose of 1580 mg/day.
PlaceboOther
Placebo contains 100% maltodextrins as non-active agent at the dose of 1800 mg/day.
| Study group | Role | What they receive |
|---|---|---|
| Chondractiv Move | Experimental | 8-week supplementation (12 weeks in ancillary subgroup) with 4 capsules/day Receives: Dietary Supplement: Chondractiv Move |
| Placebo | Placebo comparator | 8-week supplementation (12 weeks in ancillary subgroup) with 4 capsules/day Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline of activity-related joint discomfort at 8 weeks
The pain-related activity is assessed by 0-10 Visual Analogic Scale (VAS) during SLSD (Single-Leg-Step-Down) test.
Measured: Baseline (Day 0), 8 weeks (Day 56)
Secondary outcomes (16)
Change from baseline of activity-related joint discomfort at 4 weeks.
The pain-related activity is assessed by 0-10 Visual Analogic Scale (VAS) during SLSD (Single-Leg-Step-Down) test.
Measured: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline of activity-related joint discomfort at 12 weeks
The pain-related activity is assessed by 0-10 Visual Analogic Scale (VAS) during SLSD (Single-Leg-Step-Down) test.This outcome is only measured in ancillary group.
Measured: Baseline (Day 0), 4 weeks (Day 84)
Activity-related pain at regular exercise/physical activity
Average weekly pain intensity at exercise measured using 0-100 VAS (0 meaning no pain, 100 worst possible pain). At each training session or competition, the subject rates the intensity of pain perceived at exercise.
Measured: Baseline (Day 0), 4 weeks (Day 84)
Change from baseline on overall physical function at 2 weeks
Overall physical function is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS), that consists of 42 items assessing 5 dimensions: pain, other symptoms, activities of daily living, function in sport/recreation, knee related Quality of Life (QoL). KOOS is a self-assessed questionnaire.
Measured: Baseline (Day 0), 2 weeks (Day 14)
Change from baseline on overall physical function at 4 weeks
Overall physical function is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS), that consists of 42 items assessing 5 dimensions: pain, other symptoms, activities of daily living, function in sport/recreation, knee related Quality of Life (QoL). KOOS is a self-assessed questionnaire.
Measured: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline on overall physical function at 6 weeks
Overall physical function is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS), that consists of 42 items assessing 5 dimensions: pain, other symptoms, activities of daily living, function in sport/recreation, knee related Quality of Life (QoL). KOOS is a self-assessed questionnaire.
Measured: Baseline (Day 0), 6 weeks (Day 42)
Change from baseline on overall physical function at 8 weeks
Overall physical function is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS), that consists of 42 items assessing 5 dimensions: pain, other symptoms, activities of daily living, function in sport/recreation, knee related Quality of Life (QoL). KOOS is a self-assessed questionnaire.
Measured: Baseline (Day 0), 8 weeks (Day 56)
Change from baseline on overall physical function at 10 weeks
Overall physical function is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS), that consists of 42 items assessing 5 dimensions: pain, other symptoms, activities of daily living, function in sport/recreation, knee related Quality of Life (QoL). KOOS is a self-assessed questionnaire.
At week 10, outcome is only measured in ancillary subgroup.
Measured: Baseline (Day 0), 10 weeks (Day 70)
Change from baseline on overall physical function at 12 weeks
Overall physical function is measured using the Knee injury and Osteoarthritis Outcome Score (KOOS), that consists of 42 items assessing 5 dimensions: pain, other symptoms, activities of daily living, function in sport/recreation, knee related Quality of Life (QoL). KOOS is a self-assessed questionnaire.
At week 12, outcome is only measured in ancillary subgroup.
Measured: Baseline (Day 0), 12 weeks (Day 84)
Change from baseline of knee mobility at 4 weeks
Flexion and extension degrees of the knee measured using the Knee Range of Motion (ROM). Measures is carried out by the investigator using a goniometer.
Measured: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline of knee mobility at 8 weeks
Flexion and extension degrees of the knee measured using the Knee Range of Motion (ROM). Measures is carried out by the investigator using a goniometer.
Measured: Baseline (Day 0), 8 weeks (D56)
Change from baseline of knee mobility at 12 weeks
Flexion and extension degrees of the knee measured using the Knee Range of Motion (ROM). Measures is carried out by the investigator using a goniometer. At week 12, outcome is only measured in ancillary subgroup.
Measured: Baseline (Day 0), 12 weeks (Day 84)
Change from baseline of quality of life at 4 weeks
Quality of life measured using the SF-12, that consists of 12 item-short form of the generic Health-related Quality of Life SF-36. The questionnaire is a self-assessment.
Measured: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline of quality of life at 8 weeks
Quality of life measured using the SF-12, that consists of 12 item-short form of the generic Health-related Quality of Life SF-36. The questionnaire is a self-assessment.
Measured: Baseline (Day 0), 8 weeks (Day 56)
Change from baseline of quality of life at 12 weeks
Quality of life measured using the SF-12, that consists of 12 item-short form of the generic Health-related Quality of Life SF-36. The questionnaire is a self-assessment. At week 12, outcome is only measured in ancillary subgroup.
Measured: Baseline (Day 0), 12 weeks (Day 84)
Satisfaction with the supplementation
Satisfaction is assessed using a questionnaire with 5-point Likert scale ((1) Strongly disagree; (2) Disagree; (3) Neither agree nor disagree; (4) Agree; (5) Strongly agree)) or 4-point Likert scale ((1) Entirely satisfied; (2) Satisfied; (3) Not satisfied; (4) Not satisfied at all), to questions related to the perceived effectiveness.
Measured: 8 weeks (Day 56) or 12 weeks (D84) for ancillary group
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2024
- Study start25 Nov 2024
- Primary completion9 May 2025
- Study completion9 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Joint; DerangementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double-blind, randomized, placebo-controlled, single-center study with stratification by gender (\~40% men, \~60% women) and menopausal status for women (\~50% non-menopausal women, \~50% menopausal women). An ancillary subgroup with extended duration of supplementation.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 144 participants (actual)
Sponsor and investigators
- Lead sponsor
- Symrise Group
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- CEN Biotech
- Responsible party
- Sponsor
- Investigators
- Christine JUHEL, Ph.D, Study chair, CEN BiotechCarole PERRIN, MD, Principal investigator, CEN Biotech
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06714851
- Sponsor's protocol ID
- C1750
- Acronym
- MOVIPLUS
- Status last verified
- May 2025
- First submitted
- 22 Nov 2024
- Last updated
- 16 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Subjects data is not anonymized. To comply with European regulations and national provisions, subjects are informed that no sharing of IPD is planned in order to protect their personal data. If data is to be shared, patients must be informed individually, and their consent obtained. At this stage, only aggregated data can be shared
Study at a glance
From the registry record, last updated by the sponsor on 16 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Chondractiv Move (Dietary Supplement) on Activity-related Joint Discomfort in Physically Active Subjects: a Double-blind, Randomized, Placebo-controlled Study
- ClinicalTrials.gov ID
- NCT06714851
- Acronym / sponsor ID
- MOVIPLUS / C1750
- Conditions
- Joint; Derangement
- Keywords
- Activity-related joint discomfort, Collagen hydrolysate
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 144 participants (actual)
- Lead sponsor
- Symrise GroupIndustry (pharma, biotech, devices)
- Collaborators
- CEN Biotech
- Study start
- 25 Nov 2024 (actual)
- Primary completion
- 9 May 2025 (actual)
- Study completion
- 9 May 2025 (actual)
- First posted
- 4 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Joint discomfort, manifested as knee pain or gonalgia, is a common problem not only among athletes, but also among people who regularly take part in physical activities and sports. This discomfort can limit mobility and flexibility, even in healthy people who do not suffer from osteoarthritis or other joint diseases. Functional joint discomfort is also due to joint stress and the short-term deterioration of cartilage. The processes of cartilage formation and degradation lose their balance under load, and discomfort is felt for some time after exercise. These conditions and symptoms occur long before the onset of a disease such as osteoarthritis.
Dietary supplements based on herbs or collagen derivatives (a protein involved in maintaining the structure of tissues, including those of the joints) are frequently used to alleviate the discomfort associated with joint disorders and improve the balance between cartilage synthesis and degradation.
This study aims to assess the effect of the dietary supplement "Chondractiv Move" (named "Chondractiv Boost" at the time of protocol writing) on joint discomfort induced by physical activity. This is a combination of rosehip extract and hydrolyzed chicken cartilage containing collagen type II, chondroitin sulfate, and hyaluronic acid as main actives. This combination is chosen based on the results of studies showing the beneficial effects on joints of the ingredients.
Detailed description
This study requires the inclusion of about 140 participants who regularly take part in sporting activities and report knee pain during and/or after this activity.
Participants are randomly assigned to the control group receiving a placebo (a neutral product based on maltodextrins with no effect), or to the test group receiving the dietary supplement. This study is a double-blind, randomized controlled trial. This means that participants as well as assessors do not know the allocation group. This is a necessary procedure to guarantee impartiality in clinical trials.
Participants ingest placebo or dietary supplement for 8 consecutive weeks (or 12 weeks in the ancillary group with extended supplementation duration).
To assess the effect of supplementation, participants are asked to attend medical check-ups and complete questionnaires, before starting the treatment to determine basal values, and then at regular intervals, i.e. every 2 weeks or every month.
Throughout their participation, participants are monitored by the study doctor and must go to a clinical investigation center for doctors visits.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Double-blind, randomized, placebo-controlled, single-center study with stratification by gender (~40% men, ~60% women) and menopausal status for women (~50% non-menopausal women, ~50% menopausal women). An ancillary subgroup with extended duration of supplementation.
| Arm | Type | Receives |
|---|---|---|
| Chondractiv Move | Experimental | Dietary Supplement: Chondractiv Move8-week supplementation (12 weeks in ancillary subgroup) with 4 capsules/day |
| Placebo | Placebo comparator | Other: Placebo8-week supplementation (12 weeks in ancillary subgroup) with 4 capsules/day |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Body mass index ≥ 18.5 and < 30.0 kg/m2.
- Physically active: joint bearing sports (i.e., but not limited to soccer, basketball, handball, volleyball, tennis, running) for at least 3 hours per week or 2 times per week.
- Who self-report activity-related discomfort or reversible knee-joint discomfort during or immediately after physical activity over a period of at least 2 months.
- Who experience pain intensity of 5 (out of 10 on the 11 point-NRS) during the stress joint test (SLSD) and perform at least 25 repetitions.
- Who have no trouble swallowing capsules
Key exclusion criteria (10 listed)
- With diagnosed injury/trauma or tendinopathy (wiper syndrome, patellofemoral syndrome, meniscopathy), algodystrophy, osteoarthritis, rheumatic arthritis or inflammation, or other knee or joint disease.
- Extreme pain symptoms that required high-dose analgesic therapy over a longer period (>2 weeks) or intra-articular injection treatment.
- Untreated or unstable hypothyroidism, or evidence of any neurological disorders.
- Known hypersensitivity to one of the components of the experimental products (i.e., dog rose).
- Intra-articular injections or infiltrations with hyaluronic acid, plasma-rich platelet, glucosamine, chondroitin, or supplementation, with glucosamine, chondroitin, collagen-based products in the last 3 months, or spa therapy related to join health in the last 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chondractiv MoveThe dietary supplement under study (Chondractiv Move) is a combination of 2 active ingredients: Hydrolyzed chicken cartilage and Rosehip extract at the dose of 1580 mg/day. | Dietary supplement | Chondractiv Move |
| PlaceboPlacebo contains 100% maltodextrins as non-active agent at the dose of 1800 mg/day. | Other | Placebo |
Primary outcome
Change from baseline of activity-related joint discomfort at 8 weeks
Time frame: Baseline (Day 0), 8 weeks (Day 56)
The pain-related activity is assessed by 0-10 Visual Analogic Scale (VAS) during SLSD (Single-Leg-Step-Down) test.
16 secondary outcomes
Change from baseline of activity-related joint discomfort at 4 weeks.
Time frame: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline of activity-related joint discomfort at 12 weeks
Time frame: Baseline (Day 0), 4 weeks (Day 84)
Activity-related pain at regular exercise/physical activity
Time frame: Baseline (Day 0), 4 weeks (Day 84)
Change from baseline on overall physical function at 2 weeks
Time frame: Baseline (Day 0), 2 weeks (Day 14)
Change from baseline on overall physical function at 4 weeks
Time frame: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline on overall physical function at 6 weeks
Time frame: Baseline (Day 0), 6 weeks (Day 42)
Change from baseline on overall physical function at 8 weeks
Time frame: Baseline (Day 0), 8 weeks (Day 56)
Change from baseline on overall physical function at 10 weeks
Time frame: Baseline (Day 0), 10 weeks (Day 70)
Change from baseline on overall physical function at 12 weeks
Time frame: Baseline (Day 0), 12 weeks (Day 84)
Change from baseline of knee mobility at 4 weeks
Time frame: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline of knee mobility at 8 weeks
Time frame: Baseline (Day 0), 8 weeks (D56)
Change from baseline of knee mobility at 12 weeks
Time frame: Baseline (Day 0), 12 weeks (Day 84)
Change from baseline of quality of life at 4 weeks
Time frame: Baseline (Day 0), 4 weeks (Day 28)
Change from baseline of quality of life at 8 weeks
Time frame: Baseline (Day 0), 8 weeks (Day 56)
Change from baseline of quality of life at 12 weeks
Time frame: Baseline (Day 0), 12 weeks (Day 84)
Satisfaction with the supplementation
Time frame: 8 weeks (Day 56) or 12 weeks (D84) for ancillary group
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 May 2025.
- Individual participant dataSharing planned: No. Subjects data is not anonymized. To comply with European regulations and national provisions, subjects are informed that no sharing of IPD is planned in order to protect their personal data. If data is to be shared, patients must be informed individually, and their consent obtained. At this stage, only aggregated data can be shared
Related trials for Joint; Derangement
Not yet recruiting
Comparing Dextrose Prolotherapy vs. Sodium Hyaluronic Acid Injections for Jaw Joint Internal Derangement
Temporomandibular Joint Internal Derangement, TMJ-ID
Not yet recruiting
Added Diagnostic Value of CT Arthrography to MR Arthrography in Wrist Internal Derangement
Wrist Internal Derangement, Triangular Fibrocartilage Complex Tears
Active, not recruiting
Clinical Effectiveness of Combined Arthrocentesis With Intra-articular Injection of Meloxicam in Treatment of Temporomandibular Joint Internal Derangement
Temporomandibular Joint Internal Derangement
Recruiting
Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Temporomandibular Disc Displacement
Temporomandibular Disorders (TMD), Internal Derangement of the Tempromandibular Joint
Not yet recruiting
Intra-articular Injection of Medications in TMJ After Arthrocentsis
Internal Derangement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christine JUHEL, Ph.D study chair
CEN Biotech
Carole PERRIN, MD principal investigator
CEN Biotech
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chondractiv Move in people with Joint; Derangement, run by Symrise Group at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline of activity-related joint discomfort at 8 weeks (time frame: Baseline (Day 0), 8 weeks (Day 56)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2025.